Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

OncoImmunology

Volumn 7, Issue 5, 2018, Pages

  Kverneland, Anders H ^a,b   Enevold, Christian ^a   Donia, Marco ^b   Bastholt, Lars ^c   Svane, Inge Marie ^b   Nielsen, Claus H ^a  

^a Copenhagen University Hospital   (Denmark)

^b Odense University Hospital ^*  (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

anti drug antibodies; cancer; checkpoint inhibitors; immunogenicity; Ipilimumab; malignant melanoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DRUG ANTIBODY; IPILIMUMAB; TEMOZOLOMIDE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG CLEARANCE; FEMALE; HUMAN; HYPERSENSITIVITY; MALE; METASTASIS; METASTATIC MELANOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 85041611031     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2018.1424674     Document Type: Article

References (31)

1. Morse M. Technology evaluation: Ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther. 2005;7(6):588–97. PMID:16370382.
2. Cameron F, Whiteside G, Perry C. Ipilimumab: First global approval. Drugs. 2011;71(8):2079–89. doi:10.2165/11594010-000000000-00000. PMID:21985171.
3. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.0000000000000239. PMID:26558876.
4. Hodi FS, Day SJO, Mcdermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved Survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466. PMID:20525992.
5. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24(8):2174–80. doi:10.1093/annonc/mdt161. PMID:23666915.
6. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62(6):1021–8. doi:10.1007/s00262-013-1418-6. PMID:23591982.
7. McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24(10):2694–8. doi:10.1093/annonc/mdt291. PMID:23942774.
8. Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology. 2015;5(4):e1100788. doi:10.1080/2162402X.2015.1100788. PMID:27141381.
9. Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother. 2011;60(4):467–77. doi:10.1007/s00262-010-0958-2. PMID:21170646.
10. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med. 2014;371(23):2189–99. doi:10.1056/NEJMoa1406498. PMID:25409260.
11. Daud AI, Loo K, Pauli ML, Sanchez-rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, et al. Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):1–6. doi:10.1172/JCI87324.
12. Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19(14):3977–86. doi:10.1158/1078-0432.CCR-12-3243. PMID:23741070.
13. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Jr, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64. doi:10.1016/S1470-2045(09)70334-1. PMID:20004617.
14. Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611–22. doi:10.1016/S1470-2045(17)30231-0. PMID:28359784.
15. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3–10. doi:10.1016/j.ymeth.2005.01.001. PMID:15848070.
16. Vultaggio A, Nencini F, Pratesi S, Petroni G, Maggi E, Matucci A. Manifestations of antidrug antibodies response: Hypersensitivity and infusion reactions. J Interf Cytokine Res. 2014;34(12):946–52. doi:10.1089/jir.2012.0139.
17. Radstake T, Svenson M, Eijsbouts AM, van den Hoogen FHJ, Enevold C, van Riel PLCM, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739–45. doi:10.1136/ard.2008.092833. PMID:19019895.
18. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van Der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28(9):1122–6. doi:10.1111/j.1365-2036.2008.03828.x. PMID:18691349.
19. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601–8. doi:10.1056/NEJMoa020888. PMID:12584368.
20. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54(12):3782–9. doi:10.1002/art.22214. PMID:17133559.
21. Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109–17. doi:10.1056/NEJMoa074943. PMID:18337601.
22. Wolbink GJ, Aarden LA, Dijkmans B. Dealing with immunogenicity of biologicals: Assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211–5. doi:10.1097/BOR.0b013e328329ed8b. PMID:19399992.
23. FDA. Yervoy (ipilimumab) label [Internet]; 2013. Available from: http://www.accessdata.fda.gov/
24. European Medicines Agency. EPAR Yervoy [Internet]; 2011. Available from: http://www.ema.europa.eu
25. Agrawal S, Statkevich P, Bajaj G, Feng Y, Saeger S, Desai DD, Park JS, Waxman IM, Roy A, Gupta M. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Pharmacol. 2016;0(0):1–7.
26. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 2007;25(5):555–61. doi:10.1038/nbt1303. PMID:17483842.
27. Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler J. 2013 Apr 19;19(5):593–600. doi:10.1177/1352458512460604.
28. Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Mult Scler J. 2017;23(2):1–10.
29. Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;6736(17):1–10.
30. Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis. 2012;18(9):1628–33. doi:10.1002/ibd.21919. PMID:22038899.
31. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OE, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: Post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109(7):1055–64. doi:10.1038/ajg.2014.106. PMID:24796769.